Back to Main

Faculty Detail    
Campus Address THT 229 Zip 0006
Phone  (205) 934-5191
Other websites

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Infectious Diseases Professor Adjunct

Research/Clinical Interest
Dr. Victoria Johnson is Associate Professor of Medicine and a world-renowned leader in the study of HIV resistance, resistance testing, and the mechanisms of resistance development. Dr. Johnsonís track record of federal funding is impressive: NIH-NIAID R29 First Award, (91-96); NIAID R01 (96-01); PI, NIAID ACTG Developmental Virology Research Award (92-96, 96-99); PI, NIAID ACTG Adult Virology Support Laboratory Award (96-99); and PI, VA Merit Review (00-03). Her research interests involve HIV drug development and pathogenesis, especially the detection and implications of viral drug resistance. More recently, she has been investigating viral hepatitis pathogenesis and drug development, particularly for HIV/HBV and HIV/HCV co-infections. Because of her expertise in assay development and protocol development, Dr. Johnson plays an active role locally and nationally in the design and implementation of studies of antiretroviral resistance, viral load, and viral dynamics. Her laboratory studies have helped get FDA approval for several agents to treat HIV infection e.g., lamivudine (Epivir), and nelfinavir (Viracept).

Selected Publications 
Publication PUBMEDID
Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood, K, Sommadossi J-P, Pettinelli C, National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS 1999;3:6:685-94.   
Fiscus SA, Adimora AA, Schoenbach VJ, McKinney R, Lim W, Rupar D, Kenny J, Woods C, Wilfert C, Johnson VA. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 1999;180:99-105.
Gunthard HF, Leigh-Brown A, D’Aquila RT, Johnson VA, Kuritzkes D, Richman DD, Wong JK. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol independent of mutations associated with drug resistance. Virology 1999;259:154-65.   
Leigh Brown AJ, Gunthard HR, Wong JK, D’Aquila RT, Johnson VA, Kuritzkes DR, Richman DD. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. J Infect Dis 1999;180:1043-9.   
D’Aquila RT, Hughes M, Johnson VA. HIV-1 entry inhibitors and virus emergence. Nature Medicine 1999;5:1091.   
Hirsch MS, Brun-Vezinet F, D’Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417-26.   
Precious HM, Gunthard HF, Wong JK, D’Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 2000;14:31-6.   
Gilbert PB, Hanna GJ, DeGruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D’Aquila RT. Comparative analysis of HIV-1 genotypic resistance across antiretroviral trial treatment regimens. AIDS Res. Human Retroviruses 2000;16:325-36.   
Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J Infect Dis 2001;183:401-8.   
Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001; 183:1688-93.